PMC Articles for MedGen (Select 851788) - PMC

Result Filters

Links from MedGen

Items: 1 to 20 of 88

<< First< Prev

Page of 5

Select item 112249721.

Comparison of the Response to Neoadjuvant Therapy Between Immunohistochemistry HER2 (3+) and HER2 (2+)/ISH+ Early-Stage Breast Cancer: A Retrospective Multicenter Cohort Study

Dechuang Jiao, Guangyu Li, Hao Dai, Jia Wang, Jiao Zhang, Yangyang Hou, Xuhui Guo, Yajie Zhao, Xilong Gong, Zhenzhen Liu

Oncologist. 2024 Jul; 29(7): e877–e886. Published online 2024 Mar 27. doi: 10.1093/oncolo/oyae047

PMCID:: PMC11224972

Abstract Article PDF–4.3M

Select item 111014982.

Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial

Angeline Ginzac, Ioana Molnar, Xavier Durando, Thibault De La Motte Rouge, Thierry Petit, Véronique D’hondt, Mario Campone, Nathalie Bonichon-Lamichhane, Laurence Venat Bouvet, Christelle Levy, Paule Augereau, Barbara Pistilli, Olivier Arsene, Christelle Jouannaud, Suzanne Nguyen, Anne Cayre, Lucie Tixier, Céline Mahier Ait Oukhatar, Jean-Marc Nabholtz, Frédérique Penault-Llorca, Marie-Ange Mouret-Reynier

Breast Cancer Res Treat. 2024; 205(2): 267–279. Published online 2024 Mar 7. doi: 10.1007/s10549-024-07285-y

PMCID:: PMC11101498

Abstract Article PDF–2.9M

Select item 110365673.

NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer

Samuel A. Jacobs, Ying Wang, Jame Abraham, Huichen Feng, Alberto J. Montero, Corey Lipchik, Melanie Finnigan, Rachel C. Jankowitz, Mohamad A. Salkeni, Sai K. Maley, Shannon L. Puhalla, Fanny Piette, Katie Quinn, Kyle Chang, Rebecca J. Nagy, Carmen J. Allegra, Kelly Vehec, Norman Wolmark, Peter C. Lucas, Ashok Srinivasan, Katherine L. Pogue-Geile

Breast Cancer Res. 2024; 26: 69. Published online 2024 Apr 22. doi: 10.1186/s13058-024-01823-8

Correction in:: Breast Cancer Res. 2024; 26: 83.

PMCID:: PMC11036567

Abstract Article PDF–3.2M

Select item 110166574.

Pyrotinib Combined with Vinorelbine in Patients with Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Single-Arm, Prospective Study

Kuikui Jiang, Ruoxi Hong, Wen Xia, Qianyi Lu, Liang Li, Jianhao Huang, Yanxia Shi, Zhongyu Yuan, Qiufan Zheng, Xin An, Cong Xue, Jiajia Huang, Xiwen Bi, Meiting Chen, Jingmin Zhang, Fei Xu, Shusen Wang

Cancer Res Treat. 2024 Apr; 56(2): 513–521. Published online 2023 Oct 12. doi: 10.4143/crt.2023.786

PMCID:: PMC11016657

Abstract Article PDF–1.4M

Select item 110103535.

Metabolomics assisted by transcriptomics analysis to reveal metabolic characteristics and potential biomarkers associated with treatment response of neoadjuvant therapy with TCbHP regimen in HER2 + breast cancer

Ningning Zhang, Yuxin Huang, Guanwen Wang, Yimei Xiang, Zhouhong Jing, Junjie Zeng, Feng Yu, Xianjun Pan, Wenqi Zhou, Xiaohua Zeng

Breast Cancer Res. 2024; 26: 64. Published online 2024 Apr 12. doi: 10.1186/s13058-024-01813-w

PMCID:: PMC11010353

Abstract Article PDF–6.8M

Select item 109779786.

HER2 heterogeneity and treatment response–associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Zheqi Li, Otto Metzger Filho, Giuseppe Viale, Patrizia dell’Orto, Leila Russo, Marie-Anne Goyette, Avni Kamat, Denise A. Yardley, Vandana Gupta Abramson, Carlos L. Arteaga, Laura M. Spring, Kami Chiotti, Carol Halsey, Adrienne G. Waks, Tari A. King, Susan C. Lester, Jennifer R. Bellon, Eric P. Winer, Paul T. Spellman, Ian E. Krop, Kornelia Polyak

J Clin Invest. 2024 Apr 1; 134(7): e176454. Published online 2024 Feb 1. doi: 10.1172/JCI176454

PMCID:: PMC10977978

Abstract Article PDF–14M

Select item 109485707.

The role of serum thymidine kinase 1 activity in neoadjuvant-treated HER2-positive breast cancer: biomarker analysis from the Swedish phase II randomized PREDIX HER2 trial

Yajing Zhu, Ioannis Zerdes, Alexios Matikas, Ivette Raices Cruz, Mattias Bergqvist, Ellinor Elinder, Ana Bosch, Henrik Lindman, Zakaria Einbeigi, Anne Andersson, Lena Carlsson, Ann Charlotte Dreifaldt, Erika Isaksson-Friman, Mats Hellstrom, Hemming Johansson, Kang Wang, Jonas C. S. Bergh, Thomas Hatschek, Theodoros Foukakis

Breast Cancer Res Treat. 2024; 204(2): 299–308. Published online 2024 Jan 4. doi: 10.1007/s10549-023-07200-x

PMCID:: PMC10948570

Abstract Article PDF–1.0M

Select item 109130728.

Targeting HER2/HER3 co‐mutations in metastatic breast cancer: Case reports of exceptional responders to trastuzumab and pertuzumab therapy

Page E. Blas, Esther San Roman Rodriguez, Heather L. Williams, Maren K. Levin, Joshua S. K. Bell, Mariaelena Pierobon, Alexander S. Barrett, Emanuel F. Petricoin, Joyce A. O'Shaughnessy

Cancer Rep (Hoboken) 2024 Mar; 7(3): e1954. Published online 2024 Mar 5. doi: 10.1002/cnr2.1954

PMCID:: PMC10913072

Abstract Article PDF–6.4M

Select item 109118059.

Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma

Sana Hosni, Viola Kilian, Niklas Klümper, Daniela Gabbia, Katharina Sieckmann, Dillon Corvino, Anja Winkler, Miriam Saponaro, Karin Wörsdörfer, Doris Schmidt, Oliver Hahn, Ilaria Zanotto, Marina Bertlich, Marieta Toma, Tobias Bald, Markus Eckstein, Michael Hölzel, Matthias Geyer, Manuel Ritter, Dagmar Wachten, Sara De Martin, Abdullah Alajati

Cancer Res. 2024 Mar 4; 84(5): 725–740. Published online 2024 Jan 4. doi: 10.1158/0008-5472.CAN-23-1398

PMCID:: PMC10911805

Abstract Article PDF–18M

Select item 1082437510.

MyPathway Human Epidermal Growth Factor Receptor 2 Basket Study: Pertuzumab + Trastuzumab Treatment of a Tissue-Agnostic Cohort of Patients With Human Epidermal Growth Factor Receptor 2–Altered Advanced Solid Tumors

Christopher J. Sweeney, John D. Hainsworth, Ron Bose, Howard A. Burris, Razelle Kurzrock, Charles Swanton, Claire F. Friedman, David R. Spigel, Tania Szado, Katja Schulze, Richard Price, Julia Malato, Amy A. Lo, Jonathan Levy, Yong Wang, Wei Yu, Funda Meric-Bernstam

J Clin Oncol. 2024 Jan 20; 42(3): 258–265. Published online 2023 Oct 4. doi: 10.1200/JCO.22.02636

PMCID:: PMC10824375

Abstract Article PDF–788K

Select item 1078456711.

The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results

Gail D. Lewis, Guangmin Li, Jun Guo, Shang-Fan Yu, Carter T. Fields, Genee Lee, Donglu Zhang, Peter S. Dragovich, Thomas Pillow, BinQing Wei, Jack Sadowsky, Douglas Leipold, Tim Wilson, Amrita Kamath, Michael Mamounas, M. Violet Lee, Ola Saad, Voleak Choeurng, Alexander Ungewickell, Sharareh Monemi, Lisa Crocker, Kevin Kalinsky, Shanu Modi, Kyung Hae Jung, Erika Hamilton, Patricia LoRusso, Ian Krop, Melissa M. Schutten, Renee Commerford, Mark X. Sliwkowski, Eunpi Cho

Nat Commun. 2024; 15: 466. Published online 2024 Jan 11. doi: 10.1038/s41467-023-44533-z

PMCID:: PMC10784567

Abstract Article PDF–1.2M

Select item 1073527312.

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer

Guillermo Villacampa, Nadine M. Tung, Sonia Pernas, Laia Paré, Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Marta Roche-Molina, María del Monte-Millán, Mercedes Marín-Aguilera, Fara Brasó-Maristany, Adrienne G. Waks, Tomás Pascual, Olga Martínez-Sáez, Ana Vivancos, PierFranco Conte, Valentina Guarneri, Maria Vittoria Dieci, Gaia Griguolo, Javier Cortés, Antonio Llombart-Cussac, Montserrat Muñoz, Maria Vidal, Barbara Adamo, Antonio C Wolff, Angela DeMichele, Patricia Villagrasa, Joel. S. Parker, Charles M. Perou, Aranzazu Fernandez-Martinez, Lisa A. Carey, Elizabeth A. Mittendorf, Miguel Martín, Aleix Prat, Sara M. Tolaney

Ann Oncol. Author manuscript; available in PMC 2023 Dec 21.

Published in final edited form as: Ann Oncol. 2023 Sep; 34(9): 783–795. Published online 2023 Jun 9. doi: 10.1016/j.annonc.2023.05.012

PMCID:: PMC10735273

Abstract Article PDF–1.1M

Select item 1070971513.

Prognostic power assessment of clinical parameters to predict neoadjuvant response therapy in HER2‐positive breast cancer patients: A machine learning approach

Annarita Fanizzi, Agnese Latorre, Domenica Antonia Bavaro, Samantha Bove, Maria Colomba Comes, Erika Francesca Di Benedetto, Federico Fadda, Daniele La Forgia, Francesco Giotta, Gennaro Palmiotti, Nicole Petruzzellis, Lucia Rinaldi, Alessandro Rizzo, Vito Lorusso, Raffaella Massafra

Cancer Med. 2023 Nov; 12(22): 20663–20669. Published online 2023 Oct 31. doi: 10.1002/cam4.6512

PMCID:: PMC10709715

Abstract Article PDF–597K

Select item 1065402314.

Exploring the clinical outcomes and safety profile of inetetamab treatment in metastatic breast cancer patients: A multicenter assessment of a Chinese-origin recombinant Anti-HER2 monoclonal antibody

Binliang Liu, Ning Xie, Can Tian, Ronghua Feng, Zhe-Yu Hu, Jing Li, Liping Liu, Huawu Xiao, Xiaohong Yang, Mengsi Zeng, Hui Wu, Jun Lu, Jianxiang Gao, Xuming Hu, Min Cao, Zhengrong Shui, Yu Tang, Tao Wu, Quchang Ouyang

Breast. 2023 Dec; 72: 103597. Published online 2023 Nov 1. doi: 10.1016/j.breast.2023.103597

PMCID:: PMC10654023

Abstract Article PDF–2.1M

Select item 1059104215.

Deep (phospho)proteomics profiling of pre- treatment needle biopsies identifies signatures of treatment resistance in HER2⁺ breast cancer

Donna O. Debets, Kelly E. Stecker, Anastasia Piskopou, Marte C. Liefaard, Jelle Wesseling, Gabe S. Sonke, Esther H. Lips, Maarten Altelaar

Cell Rep Med. 2023 Oct 17; 4(10): 101203. Published online 2023 Oct 3. doi: 10.1016/j.xcrm.2023.101203

PMCID:: PMC10591042

Abstract Article PDF–4.4M

Select item 1054533016.

Changes in HER2 status and survival outcomes in patients with non-pathological complete response after neoadjuvant targeted treatment

Xiaofei Ren, Xiangmei Zhang, Xiangmin Ma, Chao Yang, Jingping Li, Beichen Liu, Chao Shi, Yunjiang Liu

Medicine (Baltimore) 2023 Sep 29; 102(39): e34903. Published online 2023 Sep 29. doi: 10.1097/MD.0000000000034903

PMCID:: PMC10545330

Abstract Article PDF–546K

Select item 1041090517.

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial

Jun Cao, Yuee Teng, Huiping Li, Lili Zhang, Quchang Ouyang, Weimin Xie, Yueyin Pan, Zhenchuan Song, Xiaoling Ling, Xiaohong Wu, Jingwei Xu, Li Li, Liping Ren, Hong Wang, Dongxian Zhou, Jing Luo, Xichun Hu

BMC Med. 2023; 21: 300. Published online 2023 Aug 9. doi: 10.1186/s12916-023-02999-0

PMCID:: PMC10410905

Abstract Article PDF–1.1M

Select item 1028090218.

BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer

M. C. Liefaard, A. van der Voort, M. S. van Ramshorst, J. Sanders, S. Vonk, H. M. Horlings, S. Siesling, L. de Munck, A. E. van Leeuwen, M. Kleijn, L. Mittempergher, M. M. Kuilman, A. M. Glas, J. Wesseling, E. H. Lips, G. S. Sonke

Breast Cancer Res. 2023; 25: 71. Published online 2023 Jun 19. doi: 10.1186/s13058-023-01664-x

PMCID:: PMC10280902

Abstract Article PDF–2.7M

Select item 1017618019.

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical Trial

Oleg Gluz, Ulrike A. Nitz, Matthias Christgen, Sherko Kuemmel, Johannes Holtschmidt, Johannes Schumacher, Andreas Hartkopf, Jochem Potenberg, Kerstin Lüedtke-Heckenkamp, Marianne Just, Christian Schem, Raquel von Schumann, Cornelia Kolberg-Liedtke, Christine Zu Eulenburg, Timo Schinköthe, Monika Graeser, Rachel Wuerstlein, Ronald E. Kates, Hans Heinrich Kreipe, Nadia Harbeck

JAMA Oncol. 2023 Jul; 9(7): 946–954. Published online 2023 May 11. doi: 10.1001/jamaoncol.2023.0646

PMCID:: PMC10176180

Abstract Article

Select item 1014127420.

Assessment of a Genomic Assay in Patients With ERBB2-Positive Breast Cancer Following Neoadjuvant Trastuzumab-Based Chemotherapy With or Without Pertuzumab

Coralia Bueno-Muiño, Isabel Echavarría, Sara López-Tarruella, Marta Roche-Molina, María del Monte-Millán, Tatiana Massarrah, Yolanda Jerez, Francisco Ayala de la Peña, José Ángel García-Sáenz, Fernando Moreno, Álvaro Rodríguez-Lescure, Diego Malón-Giménez, Ana Isabel Ballesteros García, Mercedes Marín-Aguilera, Patricia Galván, Fara Brasó-Maristany, Adrienne G. Waks, Sara M. Tolaney, Elizabeth A. Mittendorf, Ana Vivancos, Patricia Villagrasa, Joel. S. Parker, Charles M. Perou, Laia Paré, Guillermo Villacampa, Aleix Prat, Miguel Martín

JAMA Oncol. 2023 Jun; 9(6): 841–846. Published online 2023 Apr 27. doi: 10.1001/jamaoncol.2023.0187